Neurolentech GmbH. (4/22/24). "Press Release: Neurolentech Signs Technology Access Partnership with Kaerus Bioscience to Advance Neurodevelopmental Disorder Research". Klosterneuburg.

	Organisation	Neurolentech GmbH
	Organisation 2	Kaerus Bioscience Ltd.
	Product	NDD Drug Discovery platform (Neurodevelopmental Disorder Drug Discovery platform)
	Product 2	antiepileptic drug
	Person	Nielsen, Fiona G. G. (Repositive 201608 CEO)
	Person 2	Ring, Robert H. (Kaerus Bioscience 202404 CEO)

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes

Neurolentech, a pioneering drug discovery startup spun out of IST Austria and focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), today announced a technology access partnership with Kaerus Bioscience, a biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. The agreement enables Kaerus Bioscience to access Neurolentech’s NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens to drive advances in neurodevelopmental disorders research.

Built for NDD drug discovery, Neurolentech’s Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders. The Platform will enable Kaerus Bioscience to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.

The partnership marks a significant milestone in Neurolentech’s mission to advance drug discovery for NDDs, and further reinforces its NDD Drug Discovery platform as a valuable resource for both researchers and industry partners.

Fiona Nielsen, CEO of Neurolentech, said, “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the field of neurodevelopmental disorders. Our platform’s unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies.”

Robert Ring, CEO of Kaerus Bioscience, added, “Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”

For further information, please contact:

Neurolentech
Email: press@neurolentech.com

Kaerus Bioscience
Email: info@kaerusbio.com

About Neurolentech

Neurolentech is a biotech startup doing drug discovery for epilepsy and related genetic neurodevelopmental disorders (NDDs). The Neurolentech drug discovery platform is built on a library of human-derived iPSCs and hiPSC-derived neuronal cell models from patients across the epilepsy and NDD spectrum. Neurolentech has developed unique proprietary assays for interrogating the molecular aspects and cellular functional mechanisms of disease. With the combination of patient-derived models and assays optimized for interrogating NDD related mechanisms, Neurolentech can discover novel targets for drug discovery and screen effectiveness of potential novel therapeutics across their unique library of patient-derived models.

For more information about Neurolentech and its Neurodevelopmental Disorder Drug Discovery platform, please visit http://neurolentech.com

About Kaerus Bioscience

Kaerus Bioscience Ltd is a biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has developed a pipeline of targeted, small-molecule therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome, the most common inherited cause of intellectual disability and autism globally.

For more information about Kaerus, please visit www.kaerusbio.com

Record changed: 2024-05-08

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)